FranceFrance

French biotech companies suffer from venture capital shortage

29.04.2009

Paris – The French biotechnology industry is facing a major decline in invested venture capital according to an analysis made by France Biotech, the country’s national association of biotech companies.
The latest statistics are sobering. Funding fell by a whopping 79% in 2008 relative to 2007 – a loss of more than EUR500m, down from EUR694m in 2007 to just EUR143m in 12 months. Listed companies took the heaviest hits. In 2008, they collected only EUR12m on the public capital market, a fall of 98%. In comparison, venture capital investments in private companies dropped by “only” 27% to around EUR132m in 2008. The trend for early 2009 appears to show continued degradation, said France Bio­tech.
Philippe Pouletty, the association’s chairman, commented that “in order to underpin the optimism of our entrepreneurs, we must adopt an aggressive stimulus plan for young, innovative companies. Assuming that they can access finance, today’s innovative SMBs will become tomorrow’s multinationals, and thus constitute an essential driver of strong, sustainable economic growth.” France Bio­tech also stated that contrary to claims by French President Nicolas Sarkozy, the French government had actually weakened its support for young, innovative companies in 2009 – pointing to the budget for the OSEO (the French state innovation agency), which was slashed in half, and the reform of a national research tax credit that it says has effectively led to an average annual reduction of 56% for young biotech companies.

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/french-biotech-companies-suffer-from-venture-capital-shortage.html

Product of the week

Products

Events

All Events

Current issue

All issues